Oncology

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

News

UK's Pheon is latest kid on the block in ADC sector

There's a new player on the antibody-drug conjugate (ADC) scene.

Views & Analysis

Could vaccines soon be added to the ‘collective arsenal’ aga...

The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales.

Views & Analysis

AI diagnostics tools and oncology: predicting patient outcom...

AI French-American biotech start-up Owkin recently published new research in

News

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

Japan's Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T

News

Lava fires up a $700m cancer licensing deal with Seagen

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

UK's Pheon is latest kid on the block in ADC sector

Could vaccines soon be added to the ‘collective arsenal’ aga...

AI diagnostics tools and oncology: predicting patient outcom...

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

Lava fires up a $700m cancer licensing deal with Seagen

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

Oncology

Editor's Picks